Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Brief Summary:
This is a randomized, controlled study evaluating metformin tablets administered daily for 8
weeks. The purpose of the study is to evaluate the efficacy and safety of metformin in the
treatment of mild to moderately active ulcerative colitis. Disease activity will be measured
using Mayo score for ulcerative colitis activity. Calculation of the score requires patients
to undergo colonoscopy at the start of the study and at week 8.
Phase:
Phase 2
Details
Lead Sponsor:
National Hepatology & Tropical Medicine Research Institute